Taysha Gene Therapies, Inc. (TSHA) Stock Forecast
TSHA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.77 / 5 from 13 analysts
- Price target
- $13.00 average of analyst targets
- Upside to target
- +259.1% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.14
- 52-week range
- $3.51 – $6.98
TSHA analyst ratings
13 analystsNumber of analysts at each rating.
TSHA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TSHA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.14 | −$0.10 | −$0.09 | −42.9% | 4 |
| Current fiscal year (2026) | −$0.47 | −$0.58 | −$0.38 | −$0.32 | −49.1% | 5 |
| Next fiscal year (2027) | −$0.46 | −$0.53 | −$0.43 | −$0.47 | +2.4% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TSHA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $618,180 | $0 | $3.8M | 0.0% | 11 |
| Current fiscal year (2026) | $1.8M | $0 | $15.0M | −82.1% | 12 |
| Next fiscal year (2027) | $19.7M | $0 | $97.9M | +1,023.0% | 11 |
TSHA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TSHA revenue: reported and forecast
TSHA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.12 | −$0.12 | −$0.12 | −$0.12 | +2.5% | 0 up · 3 down |
| Current fiscal year (2026) | −$0.44 | −$0.44 | −$0.44 | −$0.47 | −$0.47 | +7.7% | 0 up · 3 down |
| Next fiscal year (2027) | −$0.44 | −$0.43 | −$0.43 | −$0.48 | −$0.46 | +4.5% | 0 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TSHA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TSHA beat in 7 of 12.
What analysts expect from TSHA
13 analysts cover Taysha Gene Therapies; their consensus rating is strong buy (4.77 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.00, 259.1% above the latest close of $3.62. Analysts expect earnings of −$0.47 per share for 2026, −49.1% from a year earlier. For 2027 the average estimate is −$0.46 per share on revenue of $19.7 million. Taysha Gene Therapies beat the EPS estimate in 7 of the last 12 quarters.
Related: TSHA income statement, TSHA key metrics, TSHA chart. See the TSHA stock overview for the latest quote and news.
TSHA forecast FAQ
What is Taysha Gene Therapies's price target?
The average analyst price target for Taysha Gene Therapies is $13.00, 259.1% above the latest close of $3.62.
Is Taysha Gene Therapies a buy, hold or sell?
Of 13 analysts covering Taysha Gene Therapies, 10 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Taysha Gene Therapies's EPS forecast?
Analysts forecast −$0.47 per share for 2026 (range −$0.58 to −$0.38); for 2027 the estimate is −$0.46.
What is Taysha Gene Therapies's revenue forecast?
The average revenue estimate for 2026 is $1.8 million, growth of −82.1%; for 2027 it is $19.7 million.
When does Taysha Gene Therapies report earnings?
Taysha Gene Therapies is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $-0.14.
Does Taysha Gene Therapies usually beat earnings estimates?
Taysha Gene Therapies reported EPS at or above the analyst estimate in 7 of the last 12 quarters.